Latest Insider Transactions at Aclaris Therapeutics, Inc. (ACRS)
This section provides a real-time view of insider transactions for Aclaris Therapeutics, Inc. (ACRS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Aclaris Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Aclaris Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 02
2024
|
Kevin Balthaser Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
427
-1.75%
|
$427
$1.24 P/Share
|
|
Mar 02
2024
|
Kevin Balthaser Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+5.79%
|
-
|
|
Mar 01
2024
|
Joseph Monahan Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
17,752
-4.82%
|
$17,752
$1.24 P/Share
|
|
Mar 01
2024
|
Joseph Monahan Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
60,925
+13.5%
|
-
|
|
Mar 01
2024
|
Neal Walker INTERIM PRESIDENT AND CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,223
-0.25%
|
$3,223
$1.24 P/Share
|
|
Mar 01
2024
|
Neal Walker INTERIM PRESIDENT AND CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
9,466
+0.73%
|
-
|
|
Mar 01
2024
|
Kevin Balthaser Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
990
-2.16%
|
$990
$1.24 P/Share
|
|
Mar 01
2024
|
Kevin Balthaser Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,475
+7.0%
|
-
|
|
Mar 01
2024
|
Andrew Kenneth William Powell |
BUY
Open market or private purchase
|
Direct |
8,500
+27.1%
|
$8,500
$1.23 P/Share
|
|
Feb 01
2024
|
James Loerop Chief Business Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,421
-9.36%
|
$6,421
$1.2 P/Share
|
|
Feb 01
2024
|
James Loerop Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
18,750
+21.24%
|
-
|
|
Feb 01
2024
|
Joseph Monahan Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,583
-1.88%
|
$2,583
$1.2 P/Share
|
|
Feb 01
2024
|
Joseph Monahan Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+5.18%
|
-
|
|
Jan 01
2024
|
Douglas J. Manion Pres and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
9,125
-17.91%
|
$9,125
$1.05 P/Share
|
|
Jan 01
2024
|
Douglas J. Manion Pres and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
27,000
+34.64%
|
-
|
|
Jan 01
2024
|
Kevin Balthaser Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,536
-11.04%
|
$2,536
$1.05 P/Share
|
|
Jan 01
2024
|
Kevin Balthaser Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+24.62%
|
-
|
|
Oct 23
2023
|
Joseph Monahan Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
6,000
-4.42%
|
$30,000
$5.08 P/Share
|
|
Sep 06
2023
|
Kevin Balthaser Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
9,490
+38.03%
|
$66,430
$7.9 P/Share
|
|
Sep 01
2023
|
Kevin Balthaser Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
285
-4.56%
|
$1,995
$7.9 P/Share
|
|
Sep 01
2023
|
Kevin Balthaser Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+13.78%
|
-
|
|
Aug 28
2023
|
James Loerop Chief Business Officer |
BUY
Open market or private purchase
|
Direct |
14,705
+40.41%
|
$88,230
$6.8 P/Share
|
|
Aug 21
2023
|
Joseph Monahan Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
6,000
-4.23%
|
$42,000
$7.32 P/Share
|
|
Aug 01
2023
|
Douglas J. Manion Pres and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,437
-15.64%
|
$39,933
$9.81 P/Share
|
|
Aug 01
2023
|
Douglas J. Manion Pres and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
15,575
+35.44%
|
-
|
|
Jul 01
2023
|
Gail Cawkwell Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,407
-36.05%
|
$54,070
$10.37 P/Share
|
|
Jul 01
2023
|
Gail Cawkwell Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+50.0%
|
-
|
|
Jun 20
2023
|
Joseph Monahan Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
6,000
-4.06%
|
$60,000
$10.28 P/Share
|
|
Jun 20
2023
|
Christopher P. Molineaux |
BUY
Exercise of conversion of derivative security
|
Direct |
16,500
+25.38%
|
$16,500
$1.41 P/Share
|
|
Jun 15
2023
|
Christopher P. Molineaux |
BUY
Exercise of conversion of derivative security
|
Direct |
249
+0.39%
|
$249
$1.12 P/Share
|
|
Jun 02
2023
|
William D. Humphries |
BUY
Exercise of conversion of derivative security
|
Direct |
4,507
+15.77%
|
-
|
|
Jun 02
2023
|
Vincent Milano |
BUY
Exercise of conversion of derivative security
|
Direct |
4,507
+36.43%
|
-
|
|
Jun 02
2023
|
Christopher P. Molineaux |
BUY
Exercise of conversion of derivative security
|
Direct |
4,507
+12.43%
|
-
|
|
Jun 02
2023
|
Maxine Gowen |
BUY
Exercise of conversion of derivative security
|
Direct |
4,507
+26.81%
|
-
|
|
Jun 02
2023
|
Bryan M. Reasons |
BUY
Exercise of conversion of derivative security
|
Direct |
4,507
+15.77%
|
-
|
|
Jun 02
2023
|
Andrew Kenneth William Powell |
BUY
Exercise of conversion of derivative security
|
Direct |
4,507
+23.88%
|
-
|
|
Jun 02
2023
|
Andrew N Schiff |
BUY
Exercise of conversion of derivative security
|
Direct |
4,507
+50.0%
|
-
|
|
Jun 02
2023
|
Anand Mehra |
BUY
Exercise of conversion of derivative security
|
Direct |
4,507
+10.43%
|
-
|
|
Mar 17
2023
|
Douglas J. Manion Pres and CEO |
BUY
Open market or private purchase
|
Direct |
6,300
+32.98%
|
$44,100
$7.86 P/Share
|
|
Mar 09
2023
|
Douglas J. Manion Pres and CEO |
BUY
Open market or private purchase
|
Direct |
6,500
+50.0%
|
$45,500
$7.74 P/Share
|
|
Mar 03
2023
|
Neal Walker INTERIM PRESIDENT AND CEO |
SELL
Open market or private sale
|
Direct |
30,240
-2.32%
|
$362,880
$12.63 P/Share
|
|
Mar 03
2023
|
Kevin Balthaser Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
894
-14.54%
|
$10,728
$12.63 P/Share
|
|
Mar 03
2023
|
Joseph Monahan Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
16,037
-9.79%
|
$192,444
$12.63 P/Share
|
|
Mar 02
2023
|
Neal Walker INTERIM PRESIDENT AND CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
18,254
+1.38%
|
-
|
|
Mar 02
2023
|
Neal Walker INTERIM PRESIDENT AND CEO |
SELL
Open market or private sale
|
Direct |
29,000
-2.21%
|
$348,000
$12.37 P/Share
|
|
Mar 02
2023
|
Kevin Balthaser Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+19.61%
|
-
|
|
Mar 02
2023
|
Kevin Balthaser Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,000
-17.7%
|
$12,000
$12.29 P/Share
|
|
Mar 02
2023
|
Joseph Monahan Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+7.09%
|
-
|
|
Mar 02
2023
|
Joseph Monahan Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
14,800
-8.91%
|
$177,600
$12.37 P/Share
|
|
Mar 01
2023
|
Neal Walker INTERIM PRESIDENT AND CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
138,425
+3.41%
|
-
|